Justin Brown, NP
Family · Fort Wayne, INNPI 1134358005
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $108,104 of the $141,902 with a category attached, or 76.2%. Corcept Therapeutics accounts for 60.9% of it on its own, with 47 other manufacturers making up the rest. 2025 is the largest year on record at $70,008, 3.6 times the $19,275 reported in 2021. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 934 payments — averaging $151.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$86K
- Novo Nordisk$41K
- AstraZeneca$6K
- Lilly USA, LLC$1K
- Abbott$769
- Tandem Diabetes Care, Inc.$735
- plus $6K from 42 others
What the payments were for
- Speaking & faculty fees$108,10476%
- Travel & lodging$16,21411%
- Food & beverage$17,51712%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$141,902 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 303 | $488,340 |
| KorlymMifepristone | 21 | $474,965 |
| MounjaroTirzepatide | 201 | $262,620 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 122 | $235,747 |
| JardianceEmpagliflozin | 110 | $125,582 |
| Tresiba Flextouch U-200Insulin Degludec | 82 | $118,908 |
| FarxigaDapagliflozin Propanediol | 72 | $79,752 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $68,024 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 37 | $66,025 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 42 | $57,821 |
| TrulicityDulaglutide | 29 | $50,293 |
| RybelsusSemaglutide | 24 | $45,241 |
| Xigduo XrDapaglifloz Propaned/Metformin | 38 | $43,830 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 64 | $37,954 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $36,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Fiasp, Novolog | $40,971 | $806,717503 claims |
| Corcept TherapeuticsKorlym | $86,413 | $474,96521 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,089 | $339,559309 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Glyxambi | $573 | $178,101167 claims |
| AstraZenecaFarxiga | $5,819 | $79,75272 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $400 | $57,82142 claims |
| AbbVieSynthroid | $273 | $10,381106 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $102 | $3,643379 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Fort Wayne
- Tracy JohnsonFort Wayne$68K
- Grant BlauveltFort Wayne$28K
- Benjamin GiarmoFort Wayne$21K
- Katarzyna SedlaczekFort Wayne$20K
- Brandy DantzerFort Wayne$18K
- Catherine RobertsFort Wayne$13K
- Adam ZuberFort Wayne$13K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.